- Aimed at accelerating development, MediciNova (NASDAQ:MNOV) announces the early termination of its proof-of-principle, open-label Phase 2 clinical trial of MN-001 (tipelukast) in patients with nonalcoholic steatohepatitis (NASH) or nonalcoholic fatty liver disease (NAFLD) with excessive levels of triglycerides in their blood (hypertriglyceridemia).
- An interim analysis showed that the study met the co-primary endpoint of a statistically significant reduction in mean serum triglycerides after eight weeks of treatment.
- On the safety front, no clinically significant safety signals were observed.
- Detailed results will be presented at the International Liver Congress 2018 on Friday, April 13, in Paris.
- Tipelukast is a small molecule anti-fibrotic and anti-inflammatory compound that exerts its effects via several mechanisms, including leukotriene receptor antagonism and inhibiting enzymes known as phosphodiesterases as well as 5-lipoxygenase. It is also under development for the treatment of moderate-to-severe ideopathic pulmonary fibrosis.
- Previously: MediciNova initiates mid-stage study of MN-001 for elevated triglycerides in NASH patients (Nov. 19, 2015)
- Now read: Your Daily Pharma Scoop: Heron Offering, Sorrento Issues Letter To Shareholders, MediciNova Setback
Original article